Can-C eye drops are the only eye drops that have been researched and clinically approved to be effective in slowing and, in some cases, reversing age-related eye disorders, including senile cataract.
Statistically, human trials indicate that Can-C eye-drops applied for approximately 6-months (into the eye twice daily), in patients who were all suffering from senile cataract, showed the following results:
- 41.5% had an improvement in the transmissivity of the lens.
- 88.9% had an improvement of glare sensitivity.
- 90% had an improvement in visual acuity.
Note: Both the quality and formula of this product are essential to efficacy and long-term safety. Can-C is the world’s first N-acetylcarnosine eye-drop to meet the strict criteria laid down by IVP and is therefore officially approved by IVP.
Babizhayev MA, Deyev AI, Yermakova NV, et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs RD 2002;3(2):87-103
Babizhayev MA, Yermakova NV, Semiletov YA, Deyev AI. The Natural Histidine-Containing Depeptide N-alpha-acetylcaarnosine as an antioxidant for ophthalmic Use. Biochemistry (Mosc). May;65(5):588-98.
Babizhayev MA, Deyev AI, Linberg LF. Lipid peroxidation as a possible cause of cataract. Mech Ageing Dev. 1988 Jul;44(1):69-889.